The original targeted intraoperative radiotherapy (TARGIT) for breast cancer using Intrabeam by Jayant S Vaidya in 2001 used in the TARGIT-A trial. Developed in collaboration with industry; INTRABEAM manufactured by Carl Zeiss. See http://www.ucl.ac.uk/~rmhkjsv/papers/targit.htm#disclaimer http://www.targit.org.uk Updates A few updates about the TARGIT technique using Intrabeam: 1. The shield on the posterior wall of the tumour bed is no longer used. 2. The posterior excision need not extend up to the pectoral fascia if adequate margin can be achieved without such an excision. 3. The transparent sterile cover for the Intrabeam is now available from the manufacturers. A few additional points that should be noted: 1. Conceptually, the fresh undisturbed tumour bed - the the empty, nearly spherical shell of normal breast tissue that surrounds the excised specimen - needs to be neatly in contact with the sphere of the Intrabeam applicator. NB the conical shaft of the applicator does no

7

12/3/2021

New Insights from the TARGIT-A trial of radiotherapy during lumpectomy for breast cancer

14

12/1/2021

Invited talk at the Association of Breast Surgeons of India Conference, 26 Nov 2021

15

12/1/2021

TARGIT-IORT for breast cancer NCRI conference Nov 2021 - 5-Min Short talk

13

12/1/2021

Invited talk at the NHS Oncology Conference 23 Nov 2021

16

12/1/2021

Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORT. Nathan J Coombs, Joel M Coombs, Uma J Vaidya, Julian Singer, Max Bulsara, Jeffrey S Tobias, Frederik Wenz, David J Joseph, Douglas A Brown, Richard Rainsbury, Tim Davidson, Douglas J A Adamson, Samuele Massarut, David Morgan, Ingrid Potyka, Tammy Corica, Mary Falzon, Norman Williams, Michael Baum, Jayant S Vaidya BMJ Open 2016;6:e010703. http://bmjopen.bmj.com/content/6/5/e010703.full http://blogs.bmj.com/bmjopen/2016/05/09/radiotherapy-during-surgery-could-save-millions-of-travel-miles-and-tonnes-of-co2/ The use of TARGIT intraoperative radiotherapy for eligible patients with breast cancer significantly reduces their journeys for treatment and has environmental benefits: 5 million miles of travel, 170 000 woman-hours and 1200 tonnes of CO2 (a forest of 100 hectares) per year in the UK

48

11/24/2018

Discussion about TARGIT IORT which is being used in treatment of breast cancer patients in over 350 centres in 35 countries, particularly its implementation in the UK More info at https://www.targit.org.uk Full Lancet paper https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61950-9/abstract Full report at https://www.journalslibrary.nihr.ac.uk/programmes/hta/076049/

77

11/20/2018